Biohaven Licenses IgG Degrader BHV-1300 to Ono for $100M in Asia
Image
New Haven, Conn. – October 08, 2026 -- Biohaven Ltd. (NYSE: BHVN) has signed a licensing and collaboration agreement with Ono Pharmaceutical Co., Ltd. (TYO: 4528), granting Ono exclusive rights to develop and commercialize Biohaven's MoDE pan IgG degrader portfolio across Japan, South Korea, Taiwan, and ASEAN member states.
Biohaven secures up to $100 million in near-term payments from Ono
The deal includes $80 million paid at execution and a further $20 million tied to a milestone expected within a year. Biohaven will also receive royalties of approximately 20 percent on net sales generated by Ono within the licensed territory. Biohaven retains all rights to the portfolio outside this region, including the United States, Europe, and China.